Beta-Blocker Duration After Myocardial Infarction
Beta-blockers should be continued for at least 3 years after a myocardial infarction in patients with normal left ventricular function, and indefinitely in those with reduced ejection fraction (≤40%) or heart failure.
Duration Based on Left Ventricular Function
Patients with Reduced Ejection Fraction (≤40%)
Continue beta-blockers indefinitely in all patients with left ventricular ejection fraction ≤40%, with or without heart failure symptoms 1. This represents a Class I recommendation with Level A evidence. Use should be limited to carvedilol, metoprolol succinate, or bisoprolol—the three agents proven to reduce mortality in this population 1.
Patients with Normal Left Ventricular Function (>40%)
Continue beta-blockers for 3 years minimum after myocardial infarction or acute coronary syndrome in patients with preserved left ventricular function 2, 1. This is a Class I recommendation with Level B evidence from the AHA/ACCF secondary prevention guidelines.
Continuation beyond 3 years is reasonable (Class IIa recommendation) in these patients, though the evidence becomes less definitive 1.
Recent Evidence and Evolving Perspectives
The most recent high-quality trial data presents a nuanced picture. The 2025 BETAMI-DANBLOCK trial 3 demonstrated that beta-blockers reduced the composite endpoint of death or major adverse cardiovascular events (hazard ratio 0.85, p=0.03) in patients with LVEF ≥40% over 3.5 years of follow-up. Notably, myocardial reinfarction was reduced (5.0% vs 6.7%, HR 0.73).
However, a 2025 meta-analysis of individual patient data 4 specifically examined patients with mildly reduced LVEF (40-49%) and found a 25% relative risk reduction in the composite endpoint (HR 0.75, p=0.031), while patients with preserved LVEF (≥50%) showed no significant benefit in pooled analyses 5, 6.
Practical Algorithm for Decision-Making
Start beta-blockers within the first 24 hours after myocardial infarction unless contraindicated (cardiogenic shock, heart block, severe bradycardia, active bronchospasm) 7.
At hospital discharge:
- LVEF ≤40%: Continue indefinitely (Class I)
- LVEF 40-49%: Continue for at least 3 years, consider indefinitely (Class I for 3 years, Class IIa beyond)
- LVEF ≥50%: Continue for 3 years (Class I), reassess thereafter
At 1-3 year follow-up in patients with LVEF ≥50%:
- If patient has angina, arrhythmias, or uncontrolled hypertension: Continue indefinitely
- If patient has none of these conditions: Reassessment is reasonable 8, though the 2023 ACC/AHA guidelines now suggest it "may be reasonable" to discontinue (Class IIb)
Important Caveats
The evidence supporting beta-blockers was largely established in the pre-reperfusion era 9, 7. Contemporary patients receive percutaneous coronary intervention, dual antiplatelet therapy, high-intensity statins, and ACE inhibitors—all of which may modify the incremental benefit of beta-blockers.
Contraindications requiring reevaluation: Patients with initial contraindications (heart failure risk, bradycardia, hypotension, heart block, bronchospasm) should be reassessed before discharge to determine subsequent eligibility 7.
Diabetes patients: The 2021 Diabetes Care guidelines specifically recommend 3-year duration in patients with prior myocardial infarction 2, aligning with general recommendations.
The 2024 ESC guidelines 10 acknowledge that the duration debate continues, particularly for patients with preserved LVEF, noting that observational data conflict on whether benefits extend beyond the first year. Three large European trials are currently underway to clarify optimal duration in this population.
In clinical practice, the safest approach remains continuing beta-blockers for at least 3 years in all post-MI patients without contraindications, with indefinite continuation for those with reduced ejection fraction or other compelling indications (heart failure, angina, arrhythmias, hypertension).